Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations

被引:50
作者
Patorno, Elisabetta [1 ,2 ]
Patrick, Amanda R. [1 ,2 ]
Garry, Elizabeth M. [1 ,2 ]
Schneeweiss, Sebastian [1 ,2 ]
Gillet, Victoria G. [1 ,2 ]
Bartels, Dorothee B. [3 ,4 ]
Masso-Gonzalez, Elvira [3 ]
Seeger, John D. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA
[2] Harvard Univ, Sch Med, Boston, MA 02120 USA
[3] Boehringer Ingelheim GmbH & Co KG, Corp Dept Global Epidemiol, Ingelheim, Germany
[4] Hannover Med Sch, Inst Epidemiol Social Med & Hlth Syst Res, Hannover, Germany
关键词
Cardiovascular outcomes; Epidemiological methods; Glucose-lowering medications; Observational studies; Review; ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; TYPE-2; DIABETES-MELLITUS; ALL-CAUSE MORTALITY; CORONARY-ARTERY-DISEASE; MARGINAL STRUCTURAL MODELS; HEALTH INSURANCE DATABASE; POPULATION-BASED COHORT; RETROSPECTIVE COHORT; PROPENSITY SCORE;
D O I
10.1007/s00125-014-3364-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Recent years have witnessed a growing body of observational literature on the association between glucose-lowering treatments and cardiovascular disease. However, many of the studies are based on designs or analyses that inadequately address the methodological challenges involved. Methods We reviewed recent observational literature on the association between glucose-lowering medications and cardiovascular outcomes and assessed the design and analysis methods used, with a focus on their ability to address specific methodological challenges. We describe and illustrate these methodological issues and their impact on observed associations, providing examples from the reviewed literature. We suggest approaches that may be employed to manage these methodological challenges. Results From the evaluation of 81 publications of observational investigations assessing the association between glucose-lowering treatments and cardiovascular outcomes, we identified the following methodological challenges: 1) handling of temporality in administrative databases; 2) handling of risks that vary with time and treatment duration; 3) definitions of the exposure risk window; 4) handling of exposures that change over time; and 5) handling of confounding by indication. Most of these methodological challenges may be suitably addressed through application of appropriate methods. Conclusions/interpretation Observational research plays an increasingly important role in the evaluation of the clinical effects of diabetes treatment. Implementation of appropriate research methods holds the promise of reducing the potential for spurious findings and the risk that the spurious findings will mislead the medical community about risks and benefits of diabetes medications.
引用
收藏
页码:2237 / 2250
页数:14
相关论文
共 132 条
  • [1] CANCER RISK IN PATIENTS WITH DIABETES-MELLITUS
    ADAMI, HO
    MCLAUGHLIN, J
    EKBOM, A
    BERNE, C
    SILVERMAN, D
    HACKER, D
    PERSSON, I
    [J]. CANCER CAUSES & CONTROL, 1991, 2 (05) : 307 - 314
  • [2] The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure
    Aguilar, David
    Bozkurt, Biykern
    Pritchett, Allison
    Petersen, Nancy J.
    Deswal, Anita
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (01) : 32 - 36
  • [3] Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study
    Andersson, C.
    Olesen, J. B.
    Hansen, P. R.
    Weeke, P.
    Norgaard, M. L.
    Jorgensen, C. H.
    Lange, T.
    Abildstrom, S. Z.
    Schramm, T. K.
    Vaag, A.
    Kober, L.
    Torp-Pedersen, C.
    Gislason, G. H.
    [J]. DIABETOLOGIA, 2010, 53 (12) : 2546 - 2553
  • [4] Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure
    Andersson, Charlotte
    Gislason, Gunnar H.
    Jorgensen, Casper H.
    Hansen, Peter R.
    Vaag, Allan
    Sorensen, Rikke
    Merie, Charlotte
    Olesen, Jonas B.
    Weeke, Peter
    Schmiegelow, Michelle
    Norgaard, Mette L.
    Kober, Lars
    Torp-Pedersen, Christian
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 94 (01) : 119 - 125
  • [5] [Anonymous], 2011, National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States
  • [6] Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart
    Anselmino, Matteo
    Oehrvik, John
    Malmberg, Klas
    Standl, Eberhard
    Ryden, Lars
    [J]. EUROPEAN HEART JOURNAL, 2008, 29 (02) : 177 - 184
  • [7] Arana A., 2004, PHARMACOEPIDEMIOLOGI, V13, pS330
  • [8] Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone
    Aronow, WS
    Ahn, C
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (05) : 556 - +
  • [9] Effect of Second-Generation Sulfonylureas on Survival in Patients With Diabetes Mellitus After Myocardial Infarction
    Arruda-Olson, Adelaide M.
    Patch, Richard K., III
    Leibson, Cynthia L.
    Vella, Adrian
    Frye, Robert L.
    Weston, Susan A.
    Killian, Jill M.
    Roger, Veronique L.
    [J]. MAYO CLINIC PROCEEDINGS, 2009, 84 (01) : 28 - 33
  • [10] Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
    Austin, Peter C.
    [J]. STATISTICS IN MEDICINE, 2009, 28 (25) : 3083 - 3107